Literature DB >> 29412116

Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall.

Mojca Lunder1,2, Miodrag Janić1, Mišo Šabovič1.   

Abstract

In Diabetes Mellitus (DM), hyperglycaemia and insulin resistance progressively lead to both microvascular and macrovascular complications. Whereas the incidence of microvascular complications is closely related to tight glycaemic control, this does not apply to macrovascular complications. Hyperglycaemia influences many interweaving molecular pathways that initially lead to increased oxidative stress, increased inflammation and endothelial dysfunction. The latter represents the initial in both types of vascular complications; it represents the "obligatory damage" in microvascular complications development and only "introductory damage" in macrovascular complications development. Other risk factors, such as arterial hypertension and dyslipidaemia, also play an important role in the progression of macrovascular complications. All these effects accumulate and lead to functional and structural arterial wall damage. In the end, all factors combined lead to the promotion of atherosclerosis and consequently major adverse cardiovascular events. If we accept the pivotal role of vascular wall impairment in the pathogenesis and progression of microvascular and macrovascular complications, treatment focused directly on the arterial wall should be one of the priorities in prevention of vascular complications in patients with DM. In this review, an innovative approach aimed at improving arterial wall dysfunction is described, which may show efficacy in clinical studies. In addition, the potential protective effects of current treatment approaches targeting the arterial wall are summarised. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Diabetes mellitus; chronic complications; endothelial dysfunction; macrovascular complications; prevention; treatment.

Year:  2019        PMID: 29412116     DOI: 10.2174/1570161116666180206113755

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  4 in total

1.  Downregulation of miRNA‑328 promotes the angiogenesis of HUVECs by regulating the PIM1 and AKT/mTOR signaling pathway under high glucose and low serum condition.

Authors:  Yan Zou; Fei Wu; Qi Liu; Xian Deng; Rui Hai; Xuemei He; Xiangyu Zhou
Journal:  Mol Med Rep       Date:  2020-05-12       Impact factor: 2.952

2.  Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.

Authors:  Mojca Lunder; Miodrag Janić; Miha Japelj; Andrej Juretič; Andrej Janež; Mišo Šabovič
Journal:  Cardiovasc Diabetol       Date:  2018-12-03       Impact factor: 9.951

Review 3.  Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients.

Authors:  Jovana Nikolajević Starčević; Miodrag Janić; Mišo Šabovič
Journal:  Int J Mol Sci       Date:  2019-03-09       Impact factor: 5.923

Review 4.  Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function.

Authors:  Yu Ding; Yongwen Zhou; Ping Ling; Xiaojun Feng; Sihui Luo; Xueying Zheng; Peter J Little; Suowen Xu; Jianping Weng
Journal:  Theranostics       Date:  2021-09-09       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.